We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PDUFA Provisions Could Harm FDA and Industry, Expert Says
PDUFA Provisions Could Harm FDA and Industry, Expert Says
August 24, 2007
Some of the provisions in the FDA Revitalization Act, S. 1082 and H.R. 2900, will be ineffective and could cripple the FDA and put unnecessary burdens on pharmaceutical companies, Center for Medicines in the Public Interest President Peter Pitts said.